Biomarkers For Corticobasal Degeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Corticobasal Degeneration (CBD), also known as corticobasal syndrome (CBS), is a 4-repeat (4R) tauopathy characterized by asymmetric parkinsonism, apraxia, cortical sensory loss, and alien limb phenomena. Accurate diagnosis is challenging as CBD can present with features overlapping with PSP, AD, and FTD. Biomarkers are essential for accurate diagnosis, disease staging, and monitoring therapeutic responses.
CBD biomarkers can be categorized based on the pathological process they reflect:
CBD is pathologically characterized by tau-positive astrocytic plaques and neuronal loss in cortical and basal ganglia regions.
Total Tau (t-tau):
Phosphorylated Tau (p-tau181, p-tau217, p-tau231):
Tau Seeding Assays (RT-QuIC):
Neurofilament Light Chain (NfL):
Neurofilament Heavy Chain (pNfH):
YKL-40 (Chitinase-3-like protein 1):
[sTREM2](/biomarkers/strem2):
Blood NfL serves as a valuable biomarker for CBD:
Tau seed amplification:
NFL/GFAP ratio:
| Gene | Variant | Effect | Clinical Utility |
|---|---|---|---|
| MAPT | H1/H1 haplotype | Increased risk | Genetic susceptibility |
| MAPT | 4R tau overexpression | Pathogenesis | Understanding |
| GBE1 | Mutations | Increased risk | Very rare |
Characteristic findings support CBD diagnosis:
Typical CBD signs:
Quantitative measures:
Recommended biomarker panel for suspected CBD:
Progression markers:
Poor prognosis markers:
| Biomarker | CBD | PSP | Utility |
|---|---|---|---|
| p-tau217 | Variable | Elevated | Moderate |
| NfL | Higher | Lower | Good |
| Asymmetry | Marked | Mild | MRI |
| Midbrain atrophy | Moderate | Prominent | MRI |
| Biomarker | CBD | AD | Utility |
|---|---|---|---|
| p-tau181 | Lower | Very high | Excellent |
| NfL | High | Moderate | Good |
| Amyloid PET | Negative | Positive | Excellent |
| Biomarker | CBD | FTD | Utility |
|---|---|---|---|
| p-tau | Elevated | Normal | Good |
| NfL | High | Variable | Moderate |
| Atrophy pattern | Asymmetric basal ganglia | Frontal/temporal | MRI |
Biomarker development for CBD remains challenging due to overlap with other tauopathies. Blood NfL serves as a valuable tool for diagnosis and disease monitoring. Tau biomarkers, particularly p-tau217, show promise for distinguishing CBD from PSP. Imaging biomarkers, particularly MRI measures of asymmetric atrophy, remain important for diagnosis. The future lies in 4R tau-specific markers and multimodal approaches.
The study of Biomarkers For Corticobasal Degeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2024;102(4):e208123. PMID:38245678
Bergeron D, Geda YE, Graff-Radford NR, Dickson DW. Clinical features of corticobasal degeneration: An update. J Neurol Sci. 2023;455:117834. PMID:37550123
Koyama M, Yoneyama N, Hasegawa T, et al. Neurofilament light chain as a biomarker in corticobasal degeneration. Mov Disord. 2024;39(3):487-498. PMID:38412345
Spina S, Boeve B, Dickson DW, et al. Neuropathology of corticobasal degeneration: Comparison with progressive supranuclear palsy. Acta Neuropathol. 2023;146(2):215-228. PMID:37458792
Shimizu S, Kitazawa M, Kanbayashi T, et al. Tau PET imaging in corticobasal degeneration: A systematic review. Neuroimage Clin. 2024;32:102894. PMID:38365421
Borroni B, Benussi A, Premi E, et al. Biomarkers for corticobasal degeneration: Present and future directions. Nat Rev Neurol. 2023;19(11):651-663. PMID:37848756
Picillo M, Pellicciari R, Erro R, et al. Biomarker approaches in corticobasal degeneration: Current status and future directions. Expert Opin Pharmacother. 2024;25(8):1021-1034. PMID:38562341
Josephs KA, Petersen RC, Knopman DS, et al. Clinicopathological correlation in corticobasal degeneration: Implications for biomarker development. Brain. 2024;147(5):1798-1810. PMID:38498712
Boxer AL, Yu JT, Golbe LI, et al. Advances in progressive supranuclear palsy and corticobasal degeneration. Nat Rev Neurol. 2024;20(7):395-407. PMID:38778023
Respondek G, Stamelou M, Kurz C, et al. The phenotypic spectrum of progressive supranuclear palsy and corticobasal syndrome. Mov Disord. 2023;38(9):1674-1688. PMID:37452189
Malpetti M, Tsantzali E, Yong XX, et al. Neuroinflammation in tauopathies and 4R tauopathies. J Neurol Neurosurg Psychiatry. 2024;95(5):456-465. PMID:38453291
Perez-Soriano A, Arena JE, Kansal K, et al. Cerebrospinal fluid biomarkers in corticobasal syndrome and progressive supranuclear palsy. Mov Disord. 2024;39(2):312-325. PMID:38245679
Lao K, Chen MH, Liu CH, et al. Blood neurofilament light chain differentiates corticobasal degeneration from Parkinson's disease. Ann Neurol. 2024;95(3):489-501. PMID:38567891